Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk Trial.

Circulation. Cardiovascular Interventions
Suzanne V ArnoldUS CoreValve Investigators

Abstract

Older adults with comorbidities who are at extreme risk for surgical aortic valve replacement may be appropriate candidates for transcatheter aortic valve replacement (TAVR). We present the 5-year clinical, echocardiographic, and health status outcomes of such patients treated with CoreValve self-expanding supra-annular TAVR. The CoreValve US Extreme Risk Pivotal Trial was a prospective, nonrandomized, single-arm clinical trial of TAVR at 41 sites in the United States. The primary outcome was all-cause mortality or major stroke. Secondary outcomes included echocardiographic parameters and patient-reported health status, assessed with the Kansas City Cardiomyopathy Questionnaire. Between February 2011 and August 2012, 639 patients with severe aortic stenosis at extreme surgical risk underwent attempted TAVR (mean age 82.8±8.4 years, 53% women, mean Society of Thoracic Surgeons Predicted Risk of Mortality 10.4±5.6%, 77% iliofemoral access). The 5-year Kaplan-Meier rate of death or major stroke was 72.6% ([95% CI, 68.4%–76.7%]; death 71.6%, major stroke 11.5%), with no significant differences according to access site. Among patients who survived 5 years, mean transvalvular gradient was 7.5±5.9 mm Hg, and 3.1% had moderate or sever...Continue Reading

References

Apr 12, 2000·Journal of the American College of Cardiology·C P GreenJ A Spertus
Oct 8, 2005·American Heart Journal·John SpertusUNKNOWN Cardiovascular Outcomes Research Consortium
Oct 22, 2010·The New England Journal of Medicine·Martin B LeonUNKNOWN PARTNER Trial Investigators
Oct 5, 2011·Circulation·Matthew R ReynoldsUNKNOWN Placement of Aortic Transcatheter Valves (PARTNER) Investigators
Mar 27, 2012·The New England Journal of Medicine·Raj R MakkarUNKNOWN PARTNER Trial Investigators
Jun 26, 2012·Journal of the American College of Cardiology·Lutz BuellesfeldStephan Windecker
Mar 25, 2014·Journal of the American College of Cardiology·Jeffrey J PopmaUNKNOWN CoreValve United States Clinical Investigators
Jun 10, 2015·Journal of the American College of Cardiology·Michael J ReardonJeffrey J Popma
Mar 18, 2017·The New England Journal of Medicine·Michael J ReardonUNKNOWN SURTAVI Investigators
Sep 27, 2018·Journal of the American College of Cardiology·Thomas G GleasonUNKNOWN CoreValve U.S. Pivotal High Risk Trial Clinical Investigators
Mar 19, 2019·The New England Journal of Medicine·Jeffrey J PopmaUNKNOWN Evolut Low Risk Trial Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.